MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) - A propensity score matched analysis.

BACKGROUND

Patients treated for clinically node-positive prostate cancer (PCa) are at high risk of recurrence. Local radiation dose escalation with brachytherapy (BT) has been shown to improve outcomes in advanced localised disease, but evidence is lacking for patients with pelvic lymph node metastases.

METHODS

We retrospectively collected data on patients treated for clinically node-positive PCa with definitive external beam radiation therapy (EBRT) and androgen-deprivation therapy (ADT), with or without dose-escalation to the prostate using high-dose-rate (HDR)-BT. The primary endpoint was metastasis-free survival (MFS). Toxicity was evaluated according to the RTOG/EORTC criteria. Survival analysis included propensity-score matching followed by log-rank tests, and multivariable Cox regression models.

KEY FINDINGS AND LIMITATIONS: We included 360 patients treated at eight centers between 2008 and 2023 with EBRT (100 %) and ADT (99.5 %), with a BT-boost to the prostate in approximately one third of the cases (33.6 %). No significant differences in MFS were observed between groups in a propensity-score matching analysis (median 84.6 vs. 77.7 months; p = 0.6); however, a subgroup analysis of patients with International Society of Urological Pathology (ISUP) 4-5 PCa (n = 139) indicated significantly improved MFS in those who received BT-boost (median 84.6 vs. 48.9 months; p = 0.007). BT-boost was an independent prognostic factor for MFS in a multivariable analysis accounting for ISUP (hazard ratio: 0.63; 95 % confidence interval: 0.4-0.98; p = 0.041). The incidence of late grade ≥ 2 gastrointestinal (GI) toxicity was significantly lower in patients treated with BT-boost (2.5 % vs. 10.9 %, p = 0.02).

CONCLUSION

BT-boost was not associated with improved outcomes in unselected patients treated with ADT and EBRT for clinically node-positive prostate cancer. However, subset analysis indicated that BT-boost was associated with improved outcomes in patients with ISUP grade 4-5 disease, and patients treated with BT-boost had lower rates of moderate or worse GI toxicity. Prospective studies are necessary to validate these findings.